Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LARS1 | Q9P2J5 | 6/20 | 0.58 |
| ▸ | FABP4 | P15090 | 11/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18019189 | 0.84 | LARS1 (0.62) | LARS1 | |
| SCHEMBL18019183 | 0.81 | LARS1 (0.64) | LARS1ALDH1A1 | |
| SCHEMBL19801165 | 0.80 | FABP4 (0.44) | FABP4 | |
| SCHEMBL5055279 | 0.78 | CIT (0.50) | LARS1 | |
| SCHEMBL18019163 | 0.77 | LARS1 (0.55) | LARS1 | |
| SCHEMBL18019128 | 0.75 | LARS1 (0.67) | LARS1LMNA | |
| SCHEMBL18019124 | 0.75 | LARS1 (0.67) | LARS1 | |
| SCHEMBL18019131 | 0.74 | LARS1 (1.00) | LARS1ALDH1A1 | |
| SCHEMBL28173973 | 0.74 | LARS1 (1.00) | LARS1ALDH1A1 | |
| SCHEMBL18019244 | 0.74 | AAK1 (0.40) | LARS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11072581-B2 | N-acyl-arylsulfonamide derivatives as aminoacyl-tRNA synthetase inhibitors | Oxford Drug Design Limited (GB) | 2021-07-27 | — | — | US | disclosed |
| US-20180022696-A1 | NOVEL N-ACYL-ARYLSULFONAMIDE DERIVATIVES AS AMINOACYL-TRNA SYNTHETASE INHIBITORS | THE LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) | 2018-01-25 | — | — | US | disclosed |
| US-20180022696-A1 | NOVEL N-ACYL-ARYLSULFONAMIDE DERIVATIVES AS AMINOACYL-TRNA SYNTHETASE INHIBITORS | THE LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) | 2018-01-25 | — | — | US | disclosed |
| WO-2016129983-A1 | NOVEL N-ACYL-ARYLSULFONAMIDE DERIVATIVES AS AMINOACYL-TRNA SYNTHETASE INHIBITORS | LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) | 2016-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022696-A1 | NOVEL N-ACYL-ARYLSULFONAMIDE DERIVATIVES AS AMINOACYL-TRNA SYNTHETASE INHIBITORS | AARS1, GARS1, ASNS | LARS1 72/4885FABP4 2909/4885ALDH1A1 2863/4885 |
| US-11072581-B2 | N-acyl-arylsulfonamide derivatives as aminoacyl-tRNA synthetase inhibitors | AARS1, ASNS, GARS1 | LARS1 77/4885FABP4 2771/4885ALDH1A1 2857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.